Skip to main navigation menu Skip to main content Skip to site footer

Some aspects of the treatment, detection, and costs of focusing on pulmonary arterial hypertension

Aspectos sobre tratamiento, detección y costos en el enfoque de la hipertensión arterial pulmonar




Section
Editorial

How to Cite
Some aspects of the treatment, detection, and costs of focusing on pulmonary arterial hypertension.
rev. colomb. neumol. [Internet]. 2013 Sep. 30 [cited 2024 Nov. 22];25(3). Disponible en: https://doi.org/10.30789/rcneumologia.v25.n3.2013.104

Dimensions
PlumX
license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Manuel Benavides Luna, MD.
    Adriana Torres Navas, MD.
      Carlos Arias Barrera, MD.

        Manuel Benavides Luna, MD.,

        Internista, Neumólogo. Grupo de Hipertensión Pulmonar Clínica Universitaria Colombia. Bogotá, Colombia.


        Adriana Torres Navas, MD.,

        Internista, Cardiólogo. Grupo de Hipertensión Pulmonar Clínica Universitaria Colombia. Bogotá, Colombia.


        Carlos Arias Barrera, MD.,

        Internista, Cardiólogo. Grupo de Hipertensión Pulmonar Clínica Universitaria Colombia. Bogotá, Colombia.



        Article visits 395 | PDF visits 619


        Downloads

        Download data is not yet available.
        1. Fishman AP. Primary pulmonary arterial hypertension: a look back. J Am Coll Cardiol. 2004;43(12 Suppl. S):2S-4S.
        2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34-41.
        3. Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60-72.
        4. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.
        5. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. N Engl J Med. 2013;369:319-329.
        6. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J. 2009;34:1219-63.
        7. National Institute for Health and Clinical Excellence. Pulmonary arterial hypertension (adults) e drugs: appraisal consultation document. [March 2008]. Disponible en: http://www.nice.org.uk/guidance/index.jsp? action1⁄4article&o1⁄439688
        8. Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009;13:1e320.
        9. Wilkens H, Grimminger F, Hoeper M, Stähler G, Ehlken B, Plesnila-Frank C, et al. Burden of pulmonary arterial hypertension in Germany. Respiratory Medicine. 2010;104:902-910.
        Sistema OJS 3.4.0.7 - Metabiblioteca |